Goldman Sachs Group Inc. Invests $131,000 in The Oncology Institute, Inc. $TOI

Key Points

• Goldman Sachs Group Inc. has invested approximately $131,000 in The Oncology Institute, acquiring 115,140 shares, which represents 0.13% of the company's stock as of the latest SEC filing.
• Several institutional investors have increased their positions in The Oncology Institute, with notable acquisitions including Josh Arnold Investment Consultant LLC, which invested $2,267,000 in the first quarter.
• The Oncology Institute's stock currently has a Buy rating from analysts with an average price target of $7.00, while the stock is priced at $3.46, down 2.3% recently.

Goldman Sachs Group Inc. acquired a new position in The Oncology Institute, Inc. (NASDAQ:TOI - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 115,140 shares of the company's stock, valued at approximately $131,000. Goldman Sachs Group Inc. owned approximately 0.13% of Oncology Institute as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Josh Arnold Investment Consultant LLC acquired a new position in shares of Oncology Institute during the first quarter worth $2,267,000. Jane Street Group LLC lifted its position in shares of Oncology Institute by 613.6% during the fourth quarter. Jane Street Group LLC now owns 127,659 shares of the company's stock worth $39,000 after purchasing an additional 109,769 shares in the last quarter. XTX Topco Ltd lifted its position in shares of Oncology Institute by 49.5% during the first quarter. XTX Topco Ltd now owns 55,698 shares of the company's stock worth $63,000 after purchasing an additional 18,448 shares in the last quarter. Citizens Financial Group Inc. RI acquired a new position in shares of Oncology Institute during the first quarter worth $71,000. Finally, WealthShield Partners LLC acquired a new position in shares of Oncology Institute during the first quarter worth $80,000. Institutional investors and hedge funds own 36.86% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Noble Financial assumed coverage on shares of Oncology Institute in a research report on Wednesday, July 23rd. They set an "outperform" rating and a $8.00 target price on the stock. B. Riley started coverage on shares of Oncology Institute in a report on Wednesday, July 16th. They issued a "buy" rating and a $6.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $7.00.

Oncology Institute Stock Down 2.3%

Oncology Institute stock opened at $3.46 on Tuesday. The company has a 50-day simple moving average of $3.57 and a 200-day simple moving average of $2.79. The firm has a market capitalization of $323.53 million, a P/E ratio of -5.09 and a beta of 0.10. The company has a debt-to-equity ratio of 14.58, a quick ratio of 1.37 and a current ratio of 1.62. The Oncology Institute, Inc. has a one year low of $0.13 and a one year high of $4.50.

Insider Activity at Oncology Institute

In other news, Director Growth I. L.P. M33 sold 6,018,168 shares of the company's stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $3.09, for a total transaction of $18,596,139.12. Following the completion of the transaction, the director owned 7,932,389 shares in the company, valued at approximately $24,511,082.01. This represents a 43.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 8.50% of the company's stock.

Oncology Institute Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.

Want to see what other hedge funds are holding TOI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Oncology Institute, Inc. (NASDAQ:TOI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.